Hepatic steatosis indices as predictors of vitamin D3 deficiency in patients with NAFLD associated with type 2 diabetes by Aludwan, Mahmoud et al.
 ORIGINAL ARTICLE ISSN 2450–7458
313
Mahmoud Aludwan1, Nazarii Kobyliak1 , Ludovico Abenavoli2 , Liudmyla Kononenko1,  
Larysa Shuliarenko1, Dmytro Kyriienko1, 3, Iuliia Komisarenko1
1Department of Endocrinology, Bogomolets National Medical University, Kyiv, Ukraine 
2University “Magna Graecia” of Catanzaro, Italy 
3Kyiv City Clinical Endocrinology Center, Kyiv, Ukraine
Hepatic steatosis indices as predictors  
of vitamin D3 deficiency in patients with 
NAFLD associated with type 2 diabetes
ABSTRACT
Background. Recently, vitamin D3 deficiency is consi­
dered one of the factors associated with the develop­
ment of non­alcoholic fatty liver disease (NAFLD). The 
aim was to evaluate steatosis indices and metabolic 
parameters in NAFLD depending on vitamin D3 status.
Methods. According to the recommendations of the 
European Society of Endocrinology, all patients were 
divided into 3 groups: group 1 — with an optimal 
level of vitamin D3 (30 ng/mL); group 2 — vitamin D3 
insufficiency (21–29 ng/mL) and group 3 — vitamin D3 
deficiency (< 20 ng/mL). 
Results. The study included 126 T2D patients with 
NAFLD diagnosed with ultrasound. The highest hepatic 
steatosis (HSI) and fatty liver (FLI) index values were 
diagnosed in vitamin D3 deficiency as compared to 
optimal group (HSI — 43.34 ± 6.59 vs. 39.67 ± 4.37; 
P = 0.032 and FLI — 79.21 ± 19.61 vs. 64.96 ± 17.72; 
P = 0.007). Triglyceride and glucose index (TyG) also 
were insignificantly elevated parallel to vitamin D3 
status worsened (P = 0.175). In multivariate logistic re­
gression analysis all steatosis indices were independent 
from transaminases activity, body mass index (BMI) and 
T2D duration associated with vitamin D3 deficiency. 
Conclusions. Hepatic steatosis indices (HSI, FLI and TyG) 
independently from anthropometric parameters and 
transaminase activity associated with D3 deficiency in 
NAFLD patients. (Clin Diabetol 2020; 9; 5: 313–320)
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Introduction 
Non-alcoholic fatty liver disease (NAFLD) is 
a non-specific, integral and multifactorial liver injury 
in patients with type 2 diabetes (T2D), obesity, insulin 
resistance (IR), metabolic syndrome, dyslipidemia and 
atherosclerosis [1, 2]. NAFLD is characterized by the ac-
cumulation of lipids within the hepatocytes exceeding 
5% according to histological examination [3]. NAFLD is 
the most common chronic liver disease in western coun-
tries and it has rised up to 60–95% [4]. Its frequency 
among adults ranges from 17 to 46% depending on the 
method of diagnosis, age, sex and ethnicity [5]. Current 
guidelines for the management of patients with NAFLD 
include the prescription of both hepatoprotective 
drugs and pharmacological correction of concomitant 
metabolic disorders such as obesity, hyperlipidemia, 
IR and T2D [6]. Therapy is mainly based on lifestyle 
changes to reduce body weight [7], and in some cases 
the use of metformin, glitazones, hypolipidemic drugs 
and TNF-a antagonists required to treat concomitant 
conditions [7, 8]. In addition, recent studies have 
shown that the use of omega-3 polyunsaturated fatty 
acids (PUFA) can reduce liver fat content [9, 10], while 
antioxidants [11–13] and probiotics [14–17] may have 
anti-inflammatory properties. 
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There has been a growing body of research in 
recent years describing the relationship between vita-
min D3 and NAFLD. However, there is still controversy 
over the existence of a cause and effect relationship. 
For example, a recent large-scale study using MRI 
spectroscopy and liver biopsy for the NAFLD diagnosis 
did not reveal an associative link between liver disease 
and vitamin D3 [18, 19]. On the other hand, it is proved 
that there is an inverse correlation between vitamin D3 
level and anthropometric parameters. This means that 
vitamin D3 can accumulate in adipose tissue in patients 
with obesity, leading to its extensive dilution, with 
subsequent formation of its plasma deficiency [20]. 
Recent meta-analysis involving 17 studies found a sig-
nificant relationship between vitamin D3 deficiency and 
NAFLD [21]. Patients with NAFLD had significantly lower 
levels of 25(OH)D3 and 1.26 times more commonly as 
compared to control were diagnosed with vitamin D3 
deficiency (OR [odds ratio] 1.26; 95% CI [confidence 
interval]: 1.17, 1.35) [21]. However, it remains unclear 
what exactly leads to vitamin D3 deficiency in patients 
with NAFLD. There is still no evidence as to whether the 
decrease in D3 level is primary due to own liver disease 
or due to a decrease in consumption, exposure to UV, 
and as a consequence of a decrease in its synthesis.
The aim of this study was to evaluate the hepatic 
steatosis indices, liver functional state and metabolic 




The study protocol was approved by the local ethics 
committees of Kyiv City Clinical Endocrinology Center 
and was conducted according to the guidelines of the 
Declaration of Helsinki from the year 1975. Prior to the 
study, purpose and methodology of the study were fully 
explained to the participants by the researchers, and 
all patients gave written informed consent before any 
study procedures were initiated.
Study design
After receiving consent, patients from Kyiv City 
Clinical Endocrinology Center were recruited for one-
center cross-sectional study. The cohort was composed 
with T2D patients over 18 years of age with concomi-
tant NAFLD.
NAFLD diagnosis was concluded according to the 
recommendations of the American Gastroenterology As-
sociation (AGA) and American Association for the Study of 
Liver Disease (AASLD) on the basis of clinical examination, 
laboratory values of lipid and carbohydrate metabolism, 
liver enzyme activities (ALT [alanine aminotransferase], 
AST [aspartate aminotransferase]), ALT/AST ratio, and 
ultrasonography (US) examination [7]. The diagnosis of 
fatty liver was based on the results of abdominal ultra-
sonography, which was done by trained technicians with 
Ultima PA (Radmir Co., Kharkiv, Ukraine). Of 4 known 
criteria (hepatorenal echo contrast, liver brightness, deep 
attenuation, and vascular blurring) [22] participants were 
required to have hepatorenal contrast and liver brightness 
to be given a diagnosis of NAFLD.
The study did not include patients with chronic 
diffuse liver disease of another etiology, such as 
chronic viral hepatitis (associated with HBV, HCV, HDV 
infection), autoimmune or drug-induced liver disease. 
Alcohol history was evaluated in all patients and pa-
tients were not included in the study when abuse was 
detected (> 210 grams of alcohol per week in men 
and > 140 grams of alcohol per week in women over 
a 2-year period). Wilson-Konovalov’s disease, congeni-
tal a1-antitrypsin deficiency and idiopathic hemochro-
matosis were also exclusion criteria. The study also did 
not include patients who reported that 3 months prior 
to baseline had taken anticonvulsant drugs or biological 
supplements with calcium or vitamin D3.
Data collection and measurement
Following informed consent, serum samples were 
collected and immediately frozen at –20°C. Appropri-
ate clinical and demographic data were obtained for 
each patient. Anthropometric parameters included 
measurements of weight and height to the nearest 
100 g and 0.5 cm, respectively. Body mass index (BMI) 
was calculated as body weight in kilograms divided by 
the square of height in meters (weight/height2). The 
waist circumference (WC) of the patient was measured 
without clothing, 1 cm above the upper anterior crest 
of the iliac, exhaled in a standing position.
 The serum 25(OH)D concentration was assessed 
using an electrochemiluminescence protein binding as-
say intended for the quantitative determination (Roche 
Diagnostics, Mannheim, Germany) with an intra-assay 
precision of < 5.5% and inter-assay precision of < 7.0%. 
The assay employs a vitamin D binding protein (VDBP) 
as capture protein, which binds to both 25-OH D3 
and 25-OH D2. The assay utilizes a 3-step incubation 
process, which has a duration of 27 minutes. In step 1, 
the sample is incubated with pretreatment reagent, 
which releases bound 25-OH vitamin D from the VDBP. 
In step 2, the pretreated sample is incubated with 
ruthenium labeled VDBP creating a complex between 
the 25-(OH) vitamin D and the ruthenylated VDBP [23]. 
The third incubation step consists in the addition of 
streptavidin-coated microparticles and 25-OH vitamin D 
labeled with biotin. The free sites of the ruthenium 
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labeled VDBP become occupied, forming a complex 
consisting of the ruthenium labeled vitamin D binding 
protein and the biotinylated 25-OH vitamin D. The en-
tire complex is bound to the solid phase via interaction 
of biotin and streptavidin [24]. Initially, the standards 
are measured, after which a calibration curve is simu-
lated, which determines the concentration of 25-(OH) 
D3 in samples in ng/mL.
 Deficiency of vitamin 25(OH)D3 was established, 
according to the European Society of Endocrinology 
(ESE) guidelines [25], when its concentration is less 
than 20 ng/mL, insufficiency — 21–29 ng/mL. 
Serum total cholesterol (TC), high density lipopro-
tein cholesterol (HDL-C) and triglyceride (TG) concentra-
tions were measured using enzymatic kits and stand-
ardized reagents (BioVendor, Czech Republic). Low 
(LDL-C) and very-low density lipoprotein cholesterol 
(VLDL-C) levels were calculated applying the Friedewald 
formula [26] only if TG were below 5,5 mmol/L; if they 
were above the mentioned cut-off, LDL-C concentra-
tions were measured through lipoprotein electropho-
resis and densitometry (BioVendor, Czech Republic). 
To assess the functional state of the liver and pan-
creas the standard biochemical methods were used 
(ERBA Lachema, Czech Republic). 
The HOMA2-IR model, which is a modernized ver-
sion of the structural mathematical model based on the 
determination of fasting plasma glucose (FPG) and fast-
ing insulin — HOMA (homeostasis model assessment), 
was used to estimate the IR, using the equation (FPG × 
fasting insulin [FPI]/22.5), first proposed by Matthews 
et al. [27]. This model can be calculated using software 
provided by the Oxford Center for Endocrinology, Dia-
betes and Metabolism and available at http://www.dtu.
ox.ac.uk/homacalculator/index.php. 
Fatty liver index (FLI) a validated prediction score 
for hepatic steatosis severity designed by Bedogni et al., 
as an algorithm in the Dionysos Nutrition & Liver Study 
[28]. The index varies from 0 to 100 and was calculated 
based on laboratory and anthropometric measures, 
including TG, gamma glutamyl transferase (GGT), BMI, 
and WC, by using the following formula:
FLI = [e0.953*loge (triglycerides) + 0.139*BMI + 0.718*loge (ggt) + 
0.053*waist circumference – 15.745)/(1 + e0.953*loge (triglycerides) + 
0.139*BMI + 0.718*loge (ggt) + 0.053*waist circumference – 15.745)]  
× 100
The triglyceride and glucose index (TyG) is a new 
method of screening for IR because it is easy to use and 
requires only two laboratory definitions [29]:
ln [fasting triglyceride (mg/dL) × fasting glucose 
(mg/dL)]/2.
Hepatic steatosis index (HSI) was calculated by the 
following formula:
HSI = 8 × (ALT/AST ratio) + BMI + 2 (if female) 
+ 2 (if DM)
A threshold of HIS > 36.0 confirms the presence of 
liver steatosis in a patient with a sensitivity of 93.1%, 
a specificity of 92.4% and a diagnostic accuracy of 
AUROC 0.812 [30]. 
Statistical analysis
The SPSS statistical package, version 21.0 (SPSS, 
Inc., Chicago, Illinois), was used for all statistical 
analyses and a P value < 0.05 was considered statisti-
cally significant. All continuous values were expressed 
as mean ± standard deviation (SD) and categorical 
variables were presented as %. Data distribution was 
analyzed using the Kolmogorov-Smirnov normality 
test. Continuous variables with parametric distribution 
were then analyzed using one-way analysis of variance 
(ANOVA) and if the results were significant, a Tuckey 
Post Hoc test was performed. Data with non-parametric 
distribution were analyzed using the Kruskall-Wallis 
test. For comparisons of categorical variables, we con-
ducted c2 test. Association between vitamin D3 levels 
and metabolic changes was assessed with univariate 
Pearson’s and partial with adjustment on sex, BMI and 
age, correlation analysis.
Univariate and multivariate logistic regression 
analyses were used to identify the risk factors associ-
ated with vitamin D3 deficiency. The odds ratios (OR) 
are given with the 95% confidence intervals (95% CI). 
Variables statistically significant in univariate analysis 
were included in the multivariate logistic regression 
analysis. Backward stepwise selection was used at 
a significance level of P < 0.10 to detect the independ-
ent risk factors for vitamin D3 deficiency.
Results
The study included 126 patients with T2D and 
concomitant NAFLD. Depending on the baseline level 
of vitamin D3 (Fig. 1), patients were allocated to one of 
3 groups based on current ESE guidelines [25].
The groups of patients included in the study 
were representative in terms of age (P = 0.187), T2D 
duration (P = 0.258) and sex. The group 1 (n = 23) 
included patients with optimal vitamin D3 levels (> 30.0 
ng/ml). The other two groups included patients with 
low baseline vitamin D3 levels: group 2 (n = 31) with 
vitamin D3 insufficiency (20–29.9 ng/mL) and group 3 
(n = 73) with vitamin D3 deficiency, which was diag-
nosed at < 20 ng/mL. 
The analysis of the obtained data showed that 
more than 90% of all examined patients revealed over-
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weight or obesity. Morbid obesity (BMI > 40.0 kg/m2) 
was diagnosed only in patients with low vitamin D3 con-
centrations. In the D3 deficiency group, morbid obesity 
was observed in 10 (13.9%) patients, which was not sig-
nificantly different from the D3 insufficiency (group 2) 
in which only 2 (6.5%) participants suffered from this 
pathology (P = 0.113). At the same time as the higher 
prevalence of obesity, we diagnosed a gradient increase 
in BMI and WC in parallel with a decrease of serum 
vitamin D3 level (Table 1). 
According to our results, there was a tendency 
to increase the transaminases activity parallel with a 
vitamin D3 decrease. However, the mean values did 
not exceed the reference ranges and no significant 
difference was observed between all studied groups. 
The activity of GGT, another indicator of the functional 
state of the liver, was also highest in the D3 deficiency 
group — 51.17 ± 19.4 U/L (P = 0.078). Alkaline 
phosphatase, total bilirubin and markers of pancreas 
exocrine function did not differ significantly across all 
study groups (Table 1). 
The values of the HOMA2-IR index was at the same 
level in optimal D3 and its insufficiency groups (2.41 
± 1.36 vs. 2.56 ± 1.44, P = 0.902). In D3 deficiency 
patients, the HOMA2-IR index was 3.07 ± 1.68 which 
was significantly higher as compared to the optimal D3 
group (P = 0.048). Our study analyzed changes in the 
hepatic steatosis indices (HSI and FLI) in the context of 
vitamin D3 status. The maximum value for both indices 
was diagnosed in patients with D3 deficiency, which 
was significantly higher as compared to optimal D3 
(HSI — 43.34 ± 6.59 vs. 39.67 ± 4.37; P = 0.032 and, 
for FLI — 79.21 ± 19.61 vs. 64.96 ± 17.72; P = 0.007 
respectively). In the D3 insufficiency group, the mean 
value for the HSI was 41.46 ± 5.55 and for the FLI — 
75.89 ± 19.02, which was not significant as compared 
to both other groups (Table 2). Elevation of TyG index 
was also observed in parallel with the worsening of D3 
status (P = 0.175).
In the vast majority of examined patients, disor-
ders of lipid metabolism were detected. Overall, we 
observed an increase in pro-atherogenic particles (TC, 
TG, VLDL-C and LDL-C), parallel with the decreasing of 
HDL-C. The most pronounced changes were observed 
in the D3 deficiency group, but as can be seen from the 
table 1 changes of lipid profile parameters, according 
to vitamin D3 status, were not significant between the 
groups.
Univariate Pearson’s analysis in the D3 insufficiency 
group found a significant correlation only for LDL and 
vitamin D3 level (r = –0.479; P = 0.038), which lost 
significance after adjusting for BMI, age, and gender 
(r = –0.440; P = 0.052). However, major changes were 
observed in patients with D3 deficiency. According to 
our data, the reverse, different in strength, but mostly 
weak, correlation is established between vitamin D3 
level and anthropometric parameters, transaminase 
activity, liver steatosis indices and lipids (Table 2). How-
ever, after adjustment for BMI, age and gender which 
are predictors that can affect D3 status, a significant 
relationship but less powerful remained only for WC 
(r = –0.342; P = 0.004), AST (r = –0.285; P = 0.018), 
GGT (r = –0.243; P = 0.044), TyG index (r = –0.294; 
P = 0.014), FLI (r = –0.255; P = 0.036) and TC (r = 
–0.280; P = 0.020) respectively (Table 2).
 In the univariate logistic regression analysis, the 
following independent predictors were associated 
with vitamin D3 deficiency in NAFLD patients — WC 
(OR 1.055; 95% CI 1.006–1.106; P = 0.004), HSI (OR 
1.108; 95% CI 1.010–1.217; P = 0.031), FLI (OR 1.034; 
95% CI 1.010–1.058; P = 0.005), TG (OR 1.716; 95% 
CI 1.016–2.897; P = 0.043) and BMI (OR 1.181; 95% 
CI 1.051–1.327; P = 0.005).
 All variables that were significant in the univariate 
analysis were included in a stepwise multiple logistic 
regression analysis. As can be seen from Table 3, we 
constructed several regression models. According to the 
results obtained, regardless of the transaminases activity 
HSI (Nagelkerke R2 = 0.215) and FLI (Nagelkerke R2 = 0.163) 
were associated with vitamin D3 deficiency. According to 
other logistic models, HSI and TyG indices (Nagelkerke 
R2 = 0.358) as well as BMI and T2D duration (Nagelkerke 
R2 = 0.328) were independent predictors associated with 
vitamin D3 deficiency in this cohort of patients (Table 3).
Figure 1. Serum vitamin D3 level in patients of different 
studies groups. Data presented as M ± SD. a, b, cValues at the 
same row with different superscript letters show significant 
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Table 1. Anthropometric, clinical and laboratory parameters in examined patients (M ± SD or %)
Parameters No deficiency 
(n = 23)
Vit. D3 insufficiency  
(21–29 ng/mL) (n = 31)
Vit. D3 deficiency  
(less 20 ng/mL) (n = 72)
P
Age (years) 64.83 ± 7.26 60.68 ± 10.08 60.72 ± 10.15 0.187
Duration of T2D (years) 14.3 ± 8.11 11.42 ± 5.92 13.42 ± 6.78 0.258
BMI [kg/m2] 28.46 ± 3.64a 31.88 ± 5.28b 32.65 ± 6.45b 0.011
WC [cm] 96.83 ± 7.94a 100.32 ± 8.37ab 105.23 ± 16.06b 0.020
ALT [IU/L] 25.76 ± 8.0 31.08 ± 21.95 32.00 ± 21.36 0.420
AST [IU/L] 26.54 ± 13.63 22.64 ± 14.27 27.63 ± 17.68 0.360
Total bilirubin [µmol/L] 11.9 ± 3.81 10.42 ± 4.12 9.62 ± 4.23 0.071
Alkaline phosphatase [IU/L] 81.33 ± 23.2 81.15 ± 23.1 79.3 ± 20.29 0.960
GGT [IU/L] 44.24 ± 17.27 43.06 ± 17.58 51.17 ± 19.4 0.078
Lipase [IU/L] 25.5 ± 12.59 45.32 ± 38.97 43.87 ± 45.63 0.577
Amylase [IU/L] 45.8 ± 14.02 44.5 ± 19.33 46.86 ± 21.45 0.963
HOMA2-IR 2.41 ± 1.36a 2,56 ± 1.44ab 3.07 ± 1.68b 0.038
HSI 39.67 ± 4.37a 41.46 ± 5.55ab 43.34 ± 6.59b 0.031
FLI 64.96 ± 17.72a 75.89 ± 19.02ab 79.21 ± 19.61b 0.010
TyG index 5.02 ± 0.26 5,13 ± 0.34 5.18 ± 0.38 0,175
TC [mmol/L] 5.43 ± 1.0 5.15 ± 1.09 5.68 ± 1.29 0.123
TG [mmol/L] 1.73 ± 0.89 2.15 ± 1.28 2,55 ± 1.75 0,052
VLDL-C [mmol/L] 0.76 ± 0.41 0.98 ± 0.62 1.13 ± 0.89 0.176
HDL-C [mmol/L] 1.6 ± 0.28 1.24 ± 0.32 1.33 ± 0.43 0.105
LDL-C [mmol/L] 2.88 ± 0.97 2.94 ± 0.65 2.93 ± 0.95 0.988
P: the difference between all study groups calculated using one-way ANOVA with Tukey Posthoc test 
a, b, cValues at the same row with different superscript letters show significant differences at P < 0.05
Table 2. Univariate Pearson’s correlation analysis between vitamin D3 amount and different parameters in patients 
according to baseline vitamin D3­status
Parameters No deficiency 
(n = 23)
Vit. D3 insufficiency 
(21–29 ng/mL)  
(n = 31)
Vit. D3 deficiency  
(less 20 ng/mL) 
(n = 72)
Age (years) –0.038 (0.863) – –0.114 (0.541) – –0.285 (0.015)* –
Sex –0.260 (0.231) – 0.113 (0.544) – –0.105 (0.381) –
BMI [kg/m2] 0.059 (0.789) – 0.138 (0.460) – –0.286 (0.015)* –
Duration of T2D (years) 0.019 (0.933) –0.102 (0.669) 0.130 (0.485) 0.328 (0.158) –0.074 (0.540) –0.009 (0.949)
WC [cm] 0.127 (0.564) 0.236 (0.317) 0.065 (0.727) –0.058 (0.809) –0.364 (0.002)* –0.342 (0.004)*
ALT [IU/L] –0.064 (0.772) –0.011 (0.964) 0.225 (0.223) –0.256 (0.276) –0.283 (0.016)* –0.166 (0.173)
AST [IU/L] –0.331 (0.122) –0.251 (0.286) 0.265 (0.150) –0.085 (0.723) –0.371 (0.001)* –0.285 (0.018)*
GGT [IU/L] –0.238 (0.274) –0.259 (0.270) 0.077 (0.682) –0.016 (0.948) –0.346 (0.003)* –0.243 (0.044)*
HOMA2-IR 0.223 (0.319) 0.230 (0.343) –0.031 (0.869) 0.250 (0.287) –0.185 (0.122) –0.093 (0.450)
HIS –0.212 (0.332) –0.272 (0.260) 0.141 (0.451) 0.329 (0.157) –0.303 (0.010)* –0.128 (0.299)
FLI –0.047 (0.830) 0.150 (0.541) 0.244 (0.186) –0.314 (0.178) –0.381 (0.001)* –0.255 (0.036)*
TyG index –0.147 (0.504) –0.004 (0.988) 0.118 (0.529) –0.209 (0.376) –0.341 (0.003)* –0.294 (0.014)*
TC [mmol/L] 0.183 (0.404) 0.180 (0.447) –0.331 (0.069) –0.402 (0.079) –0.376 (0.001)* –0.280 (0.020)*
TG [mmol/L] –0.261 (0.230) 0.207 (0.308) –0.083 (0.658) –0.110 (0.643) –0.303 (0.010)* –0.230 (0.057)
VLDL-C [mmol/L] –0.242 (0.291) 0.149 (0.554) –0.002 (0.998) –0.126 (0.597) –0.290 (0.043)* –0.229 (0.126)
HDL-C [mmol/L] 0.258 (0.238) 0.154 (0.804) 0.240 (0.323) 0.012 (0.960) 0.029 (0.851) 0.107 (0.496)
LDL-C [mmol/L] 0.011 (0.094) 0.685 (0.520) –0.479 (0.038)* –0.440 (0.052) –0.430 (0.004)* –0.228 (0.151)
The data is presented as r (P) 
*Marked statistically significant correlation
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Discussion
Vitamin D3 is a product of photosynthesis from its 
precursor 7-dehydrocholesterol in human skin under the 
influence of ultraviolet light. Thereafter, vitamin D3 under-
goes hepatic 25-hydroxylation to form 25-(OH)D3, a most 
sensitive clinical marker for vitamin D status in humans. 
The active metabolite of vitamin D3 (1, 25-dihydroxyvitamin 
D3), is synthesized in kidney by the enzyme 25-(OH)D3 1-a-
hydroxylase [31] and contributes to calcium and phosphate 
homeostasis, bone mineralization, and regulates cell prolif-
eration, differentiation and apoptosis [32, 33]. Vitamin D3 
exerts its biological effect mainly through VDR (vitamin D 
receptor), which belongs to the nuclear receptor superfam-
ily and regulates gene expression in a ligand-dependent 
manner. Their discovery and synthesis in cells of “uncon-
ventional” organs and tissues for this vitamin implies a 
wider range of physiological effects of the vitamin [34, 35].
 Data from our study, as well as recent in patients 
with biopsy proven NAFLD, demonstrated that 25 
(OH) D3 deficiency was significantly associated with 
histologic features such as hepatic steatosis, necro-
inflammatory changes and fibrosis (P < 0.001) after 
adjustment on age, sex, BMI, creatinine, calcium, IR 
and other clusters of metabolic syndrome [36]. On the 
other hand, in the retrospective pediatric study (n = 
234) with confirmed on biopsy NAFLD, the proportion 
of patients with significant fibrosis (stage ≥ 2) was 
significantly higher in patients with D3 insufficiency 
(29%) as compared to D3 deficiency — 15% (P = 0.040). 
Other pathomorphological parameters, such as severity 
of steatosis, ballooning, lobular/portal inflammation 
and total histologic score on the NAS scale, changes 
insignificantly between the groups [37]. 
In recent decades, less invasive methods of bio-
chemical NAFLD verification become increasingly 
common as for diagnosis and treatment effectiveness 
assessment. These methods can be divided into routine 
— lipid parameters, and the estimated coefficients: 
steatotest (SteatoTest®), hepatic steatosis indices (HSI 
and FLI), the NAFLD liver fat score, whose results are cal-
culated on the basis of special biochemical parameters 
[38]. The external validity of these tests is confirmed 
in the general population and in persons with morbid 
obesity, they allow with varying degrees of accuracy to 
predict the results and mortality associated with meta-
bolic, hepatic and cardiovascular manifestations [39].
The TyG Index was recently proposed as a new 
simple marker for IR. Further studies have demonstrated 
Table 3. Multiple stepwise logistic regression analysis using vitamin D­deficiency as a dependent variable and as an 
independent predictors for all factors that were significantly associated in univariate analysis
Models Regression coefficient ± SE OR (95% CI) P
Model 1 
(Nagelkerke R2 = 0.215)
Constant –5.671 ± 2.43
HSI 0.164 ± 0.062 1.178 (1.043–1.331) 0.008
ALT 0.083 ± 0.036 1.087 (1.013–1.166) 0.021
AST –0.086 ± 0.036 0.918 (0.855–0.985) 0.017
Model 2 
(Nagelkerke R2 = 0.328)
Constant –5.442 ± 3.784
BMI 0.324 ± 0.141 1.381 (1.049–1.823) 0.022
T2D duration –0.109 ± 0.058 0.896 (0.800–1.005) 0.060
Model 3 
(Nagelkerke R2 = 0.358)
Constant –22.063 ± 8.811
HSI 0.256 ± 0.121 1.292 (1.020–1.637) 0.034
TyG index 2.912 ± 1.284 18.386 (1.484–227.818) 0.023
Model 4 
(Nagelkerke R2 = 0.163)
Constant –0.635 ± 0.880
FLI 0.030 ± 0.013 1.030 (1.005–1.057) 0.021
AST –0.061 ± 0.029 0.940 (0.889–0.995) 0.032
ALT 0.057 ± 0.030 1.058 (0.997–1.123) 0.064
SE: standard error of the regression coefficient; R2: coefficient of determination
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that the TyG index is independently associated with 
hepatic steatosis [40], and a TyG threshold ≥ 8.5 is 
a sufficiently effective diagnostic marker of NAFLD with 
an AUC of 0.782 and has a higher diagnostic value as 
compared to ALT [41].
Our study first analyzed changes in hepatic steatosis 
indices with the assessment of associative relationships 
with other metabolic parameters in the context of vi-
tamin D3 status. The highest HSI and FLI index values 
were diagnosed in vitamin D3 deficiency as compared to 
optimal group. TyG also increased insignificantly parallel 
to D3 status worsened (P = 0.175). In multivariate logistic 
regression analysis all steatosis indices were independ-
ent from transaminases activity, body mass index (BMI) 
and T2D duration associated with vitamin D3 deficiency.
This study has some possible limitations. The es-
sential limitation is that NAFLD was not assessed by 
histopathological examination or by elastography. This 
fact may result in missing some number of patients 
with steatosis affecting less than 30% of hepatocytes 
and influence obtained results. The small sample size 
also may be a limiting factor, particularly in the group 
with optimal vitamin D3.
Conclusion
Our study demonstrated that in patients with 
T2D and concomitant NAFLD, the maximum values of 
hepatic steatosis indices were diagnosed in patients 
with D3 deficiency. There was an inverse correlation 
between vitamin D3 level and transaminases (AST, GGT), 
WC, steatosis indices, and total cholesterol levels. In 
the regression analysis it was proposed that steatosis 
indices may be used as independent predictors of D3 
deficiency in NAFLD patients. 
Conflict of interest
All authors of this paper have contributed to, read 
and approved the final version submitted. The contents 
of this manuscript have not been copyrighted or pub-
lished previously. The contents of this manuscript are 
not now under consideration for publication elsewhere. 
The authors declare that they have no conflict of inter-
est and funding is none.
REFERENCES
1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002; 
346(16): 1221–1231, doi: 10.1056/NEJMra011775, indexed in 
Pubmed: 11961152.
2. Mykhalchyshyn G, Kobyliak N, Bodnar P. Diagnostic accuracy of 
acyl-ghrelin and it association with non-alcoholic fatty liver disease 
in type 2 diabetic patients. J Diabetes Metab Disord. 2015; 14: 44, 
doi: 10.1186/s40200-015-0170-1, indexed in Pubmed: 25995986.
3. Abenavoli L, Falalyeyeva T, Boccuto L, et al. Obeticholic Acid: 
A new era in the treatment of nonalcoholic fatty liver disease. 
Pharmaceuticals (Basel). 2018; 11(4), doi: 10.3390/ph11040104, 
indexed in Pubmed: 30314377.
4. Adams LA, Lymp JF, St Sauver J, et al. The natural history of 
nonalcoholic fatty liver disease: a population-based cohort 
study. Gastroenterology. 2005; 129(1): 113–121, doi: 10.1053/j.
gastro.2005.04.014, indexed in Pubmed: 16012941.
5. Vernon G, Baranova A, Younossi ZM. Systematic review: the epide-
miology and natural history of non-alcoholic fatty liver disease and 
non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 
2011; 34(3): 274–285, doi: 10.1111/j.1365-2036.2011.04724.x, 
indexed in Pubmed: 21623852.
6. Sumida Y, Yoneda M. Current and future pharmacological thera-
pies for NAFLD/NASH. J Gastroenterol. 2018; 53(3): 362–376, doi: 
10.1007/s00535-017-1415-1, indexed in Pubmed: 29247356.
7. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and man-
agement of nonalcoholic fatty liver disease: Practice guidance 
from the American Association for the Study of Liver Diseases. 
Hepatology. 2018; 67(1): 328–357, doi: 10.1002/hep.29367, 
indexed in Pubmed: 28714183.
8. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD 
and NASH: trends, predictions, risk factors and prevention. Nat 
Rev Gastroenterol Hepatol. 2018; 15(1): 11–20, doi: 10.1038/
nrgastro.2017.109, indexed in Pubmed: 28930295.
9. Kobyliak N, Falalyeyeva T, Boyko N, et al. Probiotics and nutraceu-
ticals as a new frontier in obesity prevention and management. 
Diabetes Res Clin Pract. 2018; 141: 190–199, doi: 10.1016/j.
diabres.2018.05.005, indexed in Pubmed: 29772287.
10. Kobyliak N, Falalyeyeva T, Mykhalchyshyn G, et al. Probiotic and 
omega-3 polyunsaturated fatty acids supplementation reduces in-
sulin resistance, improves glycemia and obesity parameters in indi-
viduals with type 2 diabetes: A randomised controlled trial. Obesity 
Medicine. 2020; 19: 100248, doi: 10.1016/j.obmed.2020.100248.
11. Kobyliak N, Virchenko O, Falalyeyeva T, et al. Cerium dioxide na-
noparticles possess anti-inflammatory properties in the conditions 
of the obesity-associated NAFLD in rats. Biomed Pharmacother. 
2017; 90: 608–614, doi: 10.1016/j.biopha.2017.03.099, indexed 
in Pubmed: 28411553.
12. Kobyliak N, Abenavoli L, Falalyeyeva T, et al. Prevention of NAFLD 
development in rats with obesity via the improvement of pro/antioxi-
dant state by cerium dioxide nanoparticles. Clujul Med. 2016; 89(2): 
229–235, doi: 10.15386/cjmed-632, indexed in Pubmed: 27152074.
13. Abenavoli L, Greco M, Milic N, et al. Effect of mediterranean 
diet and antioxidant formulation in non-alcoholic fatty liver 
disease: a randomized study. Nutrients. 2017; 9(8), doi: 10.3390/
nu9080870, indexed in Pubmed: 28805669.
14. Kobyliak N, Abenavoli L, Falalyeyeva T, et al. Efficacy of probiotics 
and smectite in rats with non-alcoholic fatty liver disease. Ann 
Hepatol. 2018; 17(1): 153–161, doi: 10.5604/01.3001.0010.7547, 
indexed in Pubmed: 29311399.
15. Kobyliak N, Abenavoli L, Mykhalchyshyn G, et al. Probiotics 
and smectite absorbent gel formulation reduce liver stiffness, 
transaminase and cytokine levels in NAFLD associated with type 2 
diabetes: a randomized clinical study. Clinical Diabetology. 2019; 
8(4): 205–214, doi: 10.5603/dk.2019.0016.
16. Kobyliak N, Falalyeyeva T, Beregova T, et al. Probiotics for ex-
perimental obesity prevention: focus on strain dependence and 
viability of composition. Endokrynol Pol. 2017; 68(6): 659–667, 
doi: 10.5603/EP.a2017.0055, indexed in Pubmed: 29022648.
17. Kobyliak N, Falalyeyeva T, Tsyryuk O, et al. New insights on strain-
specific impacts of probiotics on insulin resistance: evidence from 
animal study. J Diabetes Metab Disord. 2020; 19(1): 289–296, doi: 
10.1007/s40200-020-00506-3, indexed in Pubmed: 32550178.
18. Catena C, Cosma C, Camozzi V, et al. Non-alcoholic fatty liver 
disease is not associated with vitamin D deficiency in essential hy-
pertension. High Blood Press Cardiovasc Prev. 2013; 20(1): 33–37, 
doi: 10.1007/s40292-013-0010-7, indexed in Pubmed: 23584921.
19. Li L, Zhang L, Pan S, et al. No significant association between 
vitamin D and nonalcoholic fatty liver disease in a Chinese 
Clinical Diabetology 2020, Vol. 9, No 5
320
population. Dig Dis Sci. 2013; 58(8): 2376–2382, doi: 10.1007/
s10620-013-2658-1, indexed in Pubmed: 23589141.
20. Drincic AT, Armas LAG, Van Diest EE, et al. Volumetric dilution, 
rather than sequestration best explains the low vitamin D status 
of obesity. Obesity (Silver Spring). 2012; 20(7): 1444–1448, doi: 
10.1038/oby.2011.404, indexed in Pubmed: 22262154.
21. Eliades M, Spyrou E, Agrawal N, et al. Meta-analysis: vitamin D 
and non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 
2013; 38(3): 246–254, doi: 10.1111/apt.12377, indexed in 
Pubmed: 23786213.
22. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome 
as a predictor of nonalcoholic fatty liver disease. Ann Intern 
Med. 2005; 143(10): 722–728, doi: 10.7326/0003-4819-143-10-
200511150-00009, indexed in Pubmed: 16287793.
23. Aludwan MB, Kobyliak NM, Komisarenko Y. Metabolic predic-
tors and vitamin D deficiency in patients with type 2 diabetes 
mellitus. International J Endocrinol. 2019; 15(6): 459–468, doi: 
10.22141/2224-0721.15.6.2019.185408.
24. Abdel-Wareth L, Haq A, Turner A, et al. Total vitamin D assay 
comparison of the Roche Diagnostics «Vitamin D total» electro-
chemiluminescence protein binding assay with the Chromsystems 
HPLC method in a population with both D2 and D3 forms of vita-
min D. Nutrients. 2013; 5(3): 971–980, doi: 10.3390/nu5030971, 
indexed in Pubmed: 23525081.
25. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Endocrine Society. 
Evaluation, treatment, and prevention of vitamin D deficiency: 
an Endocrine Society clinical practice guideline. J Clin Endocrinol 
Metab. 2011; 96(7): 1911–1930, doi: 10.1210/jc.2011-0385, 
indexed in Pubmed: 21646368.
26. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the 
concentration of low-density lipoprotein cholesterol in plasma, 
without use of the preparative ultracentrifuge. Clin Chem. 1972; 
18(6): 499–502, indexed in Pubmed: 4337382.
27. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model 
assessment: insulin resistance and beta-cell function from fasting 
plasma glucose and insulin concentrations in man. Diabetologia. 
1985; 28(7): 412–419, doi: 10.1007/BF00280883, indexed in 
Pubmed: 3899825.
28. Bedogni G, Miglioli L, Masutti F, et al. The Fatty Liver Index: 
a simple and accurate predictor of hepatic steatosis in the 
general population. BMC Gastroenterol. 2006; 6(5): 33–1391, 
doi: 10.1186/1471-230X-6-33, indexed in Pubmed: 17081293.
29. Unger G, Benozzi SF, Perruzza F, et al. Triglycerides and glucose 
index: a useful indicator of insulin resistance. Endocrinol Nutr. 
2014; 61(10): 533–540, doi: 10.1016/j.endonu.2014.06.009, 
indexed in Pubmed: 25174769.
30. Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple 
screening tool reflecting nonalcoholic fatty liver disease. Dig 
Liver Dis. 2010; 42(7): 503–508, doi: 10.1016/j.dld.2009.08.002, 
indexed in Pubmed: 19766548.
31. Holick MF. Vitamin D: a D-Lightful health perspective. Nutr 
Rev. 2008; 66(10 Suppl 2): S182–S194, doi: 10.1111/j.1753-
4887.2008.00104.x, indexed in Pubmed: 18844847.
32. Verstuyf A, Carmeliet G, Bouillon R, et al. Vitamin D: a pleiotropic 
hormone. Kidney Int. 2010; 78(2): 140–145, doi: 10.1038/
ki.2010.17, indexed in Pubmed: 20182414.
33. Ingraham BA, Bragdon B, Nohe A. Molecular basis of the potential of 
vitamin D to prevent cancer. Curr Med Res Opin. 2008; 24(1): 139–149, 
doi: 10.1185/030079908x253519, indexed in Pubmed: 18034918.
34. Komisarenko YI, Bobryk MI. Vitamin D deficiency and immune 
disorders in combined endocrine pathology. Front Endocrinol 
(Lausanne). 2018; 9: 600, doi: 10.3389/fendo.2018.00600, 
indexed in Pubmed: 30356853.
35. Mazanova A, Shymanskyi I, Lisakovska O, et al. Effects of 
cholecalciferol on key components of vitamin D-endo/para/
autocrine system in experimental type 1 diabetes. Int J Endocrinol. 
2018; 2018: 2494016, doi: 10.1155/2018/2494016, indexed in 
Pubmed: 29552033.
36. Targher G, Bertolini L, Scala L, et al. Associations between 
serum 25-hydroxyvitamin D3 concentrations and liver histology 
in patients with non-alcoholic fatty liver disease. Nutr 
Metab Cardiovasc Dis. 2007; 17(7): 517–524, doi: 10.1016/j.
numecd.2006.04.002, indexed in Pubmed: 16928437.
37. Yodoshi T, Orkin S, Arce-Clachar AC, et al. Vitamin D deficiency: 
prevalence and association with liver disease severity in pediatric 
nonalcoholic fatty liver disease. Eur J Clin Nutr. 2020; 74(3): 
427–435, doi: 10.1038/s41430-019-0493-y, indexed in Pubmed: 
31444465.
38. Blond E, Disse E, Cuerq C, et al. EASL-EASD-EASO clinical practice 
guidelines for the management of non-alcoholic fatty liver 
disease in severely obese people: do they lead to over-referral? 
Diabetologia. 2017; 60(7): 1218–1222, doi: 10.1007/s00125-017-
4264-9, indexed in Pubmed: 28352941.
39. Gómez-Ambrosi J, Silva C, Galofré JC, et al. Body mass index 
classification misses subjects with increased cardiometabolic 
risk factors related to elevated adiposity. Int J Obes (Lond). 2012; 
36(2): 286–294, doi: 10.1038/ijo.2011.100, indexed in Pubmed: 
21587201.
40. Petta S, Di Marco V, Di Stefano R, et al. TyG index, HOMA score 
and viral load in patients with chronic hepatitis C due to genotype 
1. J Viral Hepat. 2011; 18(7): e372–e380, doi: 10.1111/j.1365-
2893.2011.01439.x, indexed in Pubmed: 21692950.
41. Zhang S, Du T, Zhang J, et al. The triglyceride and glucose index 
(TyG) is an effective biomarker to identify nonalcoholic fatty liver 
disease. Lipids Health Dis. 2017; 16(1): 15, doi: 10.1186/s12944-
017-0409-6, indexed in Pubmed: 28103934.
